Our patenting strategy is focused on obtaining broad protection for our technologies, extension of patent life and territorial coverage. As part of this strategy, we have claimed composition of matter and method of treatment or therapeutic uses of our stem cell lines, products and their formulations in clinical or preclinical development. We have a new portfolio of patents on the production, characterisation and use of therapeutic exosomes derived from stem cells.
Applications are focused on the United States, Europe, Japan, Australia and Canada, and for more recent filings we have also included emerging economic powerhouses such as China, Brazil and South Korea for key patents. In aggregate, we have written or exclusively licensed over 80 issued patents.